Updates in Upper GI Cancers From ASCO and ASCO GI 2024 - Episode 2

4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

,

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.

EP. 1: Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm
Now Viewing
EP. 2: 4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer
EP. 3: A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer
EP. 4: Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC
EP. 5: Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC
EP. 6: Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers

Related Content:

Memorial Sloan Kettering Cancer Center Fred Hutch Cancer CenterGastrointestinal CancerImmuno-Oncology
Combination Regimens Make Their Mark in Frontline HCC
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC